linjc16/ctgov huggingface dataset:
Chest Compression and Cerebral Oxygenation During Cardiopulmonary Resuscitation

Study Overview
=================
Brief Summary
-----------------
In recent years, monitorizations during Cardiopulmonary Resuscitation (CPR) are inadequate to show the sufficiency of cerebral oxygenation. During CPR, insufficient chest compressions have critical importance for neurological results and life quality after the return of spontaneous circulation (ROSC).

Detailed Description
-----------------
The Near-Infrared Spectroscopy (NIRS), which is used in measuring the cerebral tissue oxygenation is one of the latest technologies that allow the measurement of brain oxygen saturation. With this study, the issue of whether sufficient cerebral oxygenation is provided during CPR applied to patients that have Cardiac Arrest (CA) will be investigated, and the effect of CPR on the patient prognosis after ROSC will be examined. In this study, the aim is to investigate whether sufficient oxygenation is provided in synchronization with chest compressions during CPR; and to test the regional brain tissue saturation with rSO2 measurement, and the prognosis with Full Outline of UnResponsiveness (FOUR) Score in patients with ROSC.

Official Title
-----------------
Can Sufficient Cerebral Oxygenation be Provided in a Synchronized Manner With Chest Compression During Cardiopulmonary Resuscitation?

Conditions
-----------------
Providing Sufficient Cerebral Oxygenation During CPR

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. All patients undergoing cardiac arrest in intensive care unit Exclusion Criteria: Head injury and intracranial bleeding Cerebral ischemic vascular event Pulmonary diseases that may affect blood-oxygen levels Below the age of 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The levels of regional brain tissue oxygen saturation (rSO2) providing with chest compressions during Cardiopulmonary Resuscitation (CPR) | The data will be obtained by using the Near Infrared Spectroscopy (NIRS) Device and will be recorded rSO2 measurement during the resuscitation of the Cardiac Arrest (CA) patients | About six month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in consciousness on Full Outline of UnResponsiveness (FOUR) Score at one week | The patient's consciousness will be evaluated by FOUR score in patients with ROSC | For a week after ROSC | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Oxygenation, Cardiopulmonary Resuscitation, Chest Compression
Influence of Glidescope Assisted Endotracheal Intubation on Intraocular Presure

Study Overview
=================
Brief Summary
-----------------
Tracheal intubation with traditional Macintosh laryngoscope is associated with increase in intraocular pressure along with tachycardia and hypertension. These effects are not desirable in ophthalmic patients especially in patients with glaucoma. GlideScope video laryngoscope system is a new approach for laryngoscopy and tracheal intubation. It does not require a direct line of sight to the glottis when intubating with the Glidescope and as a result intubation is much less stimulating to the patient. Therefore GlideScope video laryngoscope assisted intubation could be a preferable technique for intraocular surgery offering advantages in terms of intraocular pressure and cardiovascular stability.

Conditions
-----------------
Effect of Intubation on Intraocular Pressure

Intervention / Treatment
-----------------
* Device: Intubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status 1 or 2 with normal intra-ocular pressure. Exclusion Criteria: history or occurrence of difficult intubation. presence of previous anterior segment pathology. previous intraocular surgery. patients with history of glaucoma. brain pathology and other neurological disorder which might affect to their intraocular pressure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Macintoch group<br>Intubation with Macintoch Laryngoscope | Device: Intubation<br>* Endotracheal intubation<br>|
| Experimental: Glidescope<br>Inubation by Glidescope | Device: Intubation<br>* Endotracheal intubation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular pressure |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Airtraq, Intraocular pressure
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)

Study Overview
=================
Brief Summary
-----------------
This study objective is to assess the short and long term effects of partially hydrolyzed guar gum (PHGG) administration on clinical symptoms of IBS and quality of life of these patients.

Official Title
-----------------
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study

Conditions
-----------------
IBS

Intervention / Treatment
-----------------
* Dietary Supplement: PHGG
* Dietary Supplement: Maltodextrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fulfillment of the Rome III criteria for IBS. Aged 20-68 years at the time of screening. Provision of written informed consent. Commitment of availability throughout the 6 months study period. Exclusion Criteria: Major abdominal surgery in the past. The presence of any active (organic)GI disease. Past or present major medical or psychiatric illness. Any concomitant disease. Alarming symptoms (rectal bleeding, weight loss, etc.) Pregnancy. Family history of colorectal carcinoma or inflammatory bowel disease (IBD). Abnormal laboratory studies (blood biochemistry , liver enzymes,complete blood count), abnormal thyroid function. Non-adjusted diet in the case of lactose or gluten intolerance. Recent travel to regions with endemic parasitic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PHGG<br>2.5gr per day for the first week and then 5gr per day for 11 weeks. | Dietary Supplement: PHGG<br> <br> |
| Placebo Comparator: Maltodextrin<br>2.5gr per day for the first week and then 5gr per day for 11 weeks. | Dietary Supplement: Maltodextrin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in IBS score. | IBS scoring - Francis severity IBS score. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality questionnaire | Quality of life - by the IBS - quality of life questionnaire - Drossman Patrick. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBS, Diarrhea, Constipation, Fibers
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is examine the efficacy of a combination physical exercise and cognitive training program on improving memory in older Veterans with amnestic Mild Cognitive Impairment.

Official Title
-----------------
A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment

Conditions
-----------------
Amnestic Mild Cognitive Impairment

Intervention / Treatment
-----------------
* Behavioral: Combined Aerobic and Resistance Exercise
* Behavioral: Stretching Exercises
* Behavioral: Cognitive Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of amnestic Mild Cognitive Impairment available informant visual and auditory acuity to allow neuropsychological testing willingness to participate in exercise training + cognitive training for 8 months approval of primary provider to participate in exercise trial Exclusion Criteria: current severe psychiatric disorder diagnosis of dementia history of neurological or system illness affecting CNS function acute illness or unstable chronic illness current severe cardiac disease inability to exercise consistently because of orthopedic or musculoskeletal problems morbid obesity inability to read, verbalize understanding and voluntarily sign the informed consent

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Combined Aerobic and Resistance Exercise/Cognitive Training<br> | Behavioral: Combined Aerobic and Resistance Exercise<br>* Gym and home based aerobic and resistance exercises<br>Behavioral: Cognitive Training<br>* Group-based cognitive training<br>|
| Active Comparator: Stretching Exercises/Cognitive Training<br> | Behavioral: Stretching Exercises<br>* Gym and home based stretching exercises<br>Behavioral: Cognitive Training<br>* Group-based cognitive training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline to 28 weeks in delayed recall of a word list |  | Baseline, 24 weeks, 28 weeks | 
| Change from Baseline to 28 weeks in Delayed Recall of Names-Face Task |  | Baseline, 24 weeks, 28 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Non-Cognitive Outcomes (Depression, Sleep, Quality of Life) |  | Baseline, Time 2, Time 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mild Cognitive Impairment, Aging
Topic Compatibility Lactoserum (Dermacyd Delicata - New Fragrance)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd Femina Delicata.

Official Title
-----------------
Dermatological Evaluation of Topic Compatibility (Primary and Accumulated Dermical Irritability and Dermical Sensitivity) for Dermacyd Femina Delicata

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: Lactoserum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Phototypes: I, II, III and IV Integral skin test in the region Exclusion Criteria: Pregnancy or breastfeeding women Use of antinflammatory or immune-suppression drugs Personal history of atopy History of sensibilization or irritation for topic products Active cutaneous disease Use of new drugs and/or cosmetics during the study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Lactoserum|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score evaluation of the cutaneous reaction, preconized by International Contact Dermatitis Research Group (ICDRG) |  | six weeks |
Intra- Versus Extraarticular Injection of Ropivacaine in Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the optimal site for application of local anesthetics in total knee arthroplasty surgery. The hypothesis is, that improved pain relief is obtained when administering local anesthetics in the tissues sourrounding the knee joint compared to the knee joint itself.

Official Title
-----------------
Intraartikulær Versus ekstraartikulær Bolus Injektion Med Ropivacain Ved Total knæalloplastik: et Prospektivt, Randomiseret, Dobbeltblindet, Kontrolleret Studie

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Drug: intraarticular injection with ropivacaine
* Drug: extraarticular injection with ropivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: eligible for elective total knee arthroplasty able to speak and understand Danish able to give informed consent Exclusion Criteria: alocohol or medical abuse allergies to local anesthetics age < 18 yrs. intolerance to opioids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>intraarticular injection with local anesthetic | Drug: intraarticular injection with ropivacaine<br> <br> |
| Experimental: 2<br>intracapsular injection with local anesthetic | Drug: extraarticular injection with ropivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain |  | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pain, Postoperative
Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
Cancer is a well known complication about long term transplantation. Cancer outcomes are due to the immunosuppressive treatment that prevents transplanted people from rejection. By lowering the effectiveness of the immune system, immune cells are no longer able to seek and destroy cancer cells. The goal here is to study immunes cells population of people that were transplanted 10 years ago and are now treated either by a corticosteroid - azathioprine association, or only by cyclosporine A.

Official Title
-----------------
Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation

Conditions
-----------------
Kidney Transplant; Complications

Intervention / Treatment
-----------------
* Biological: Immune cells population assesment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 Patients with kidney transplantation for 10 year Patients with stable renal function (less than 20% creatinine variation during the last 12 months) Patients treated either by a corticosteroid - azathioprine association or cyclosporine A Patients giving his agreement Patients legally free Exclusion Criteria: Patients under 18 Patients under legal protection Pregnant women, or of age to get pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: ELITE<br> | Biological: Immune cells population assesment<br>* T lymphocytes population description through blood, urine and faeces samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune cells study | Study 2 types of T lymphocytes (by flow cytometry) that are suspected to be responsible of the graft non rejection and the cancer outcome, treated by corticosteroid - azathioprine association or cyclosporine A | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacteria study | Study the modification of the intestinal bacteria population that might led to an operational tolerance, depending on the immunosuppressive treatment : the DNA will be extracted from the faeces and a typing will be carried out by Polymerase Chain Reaction | 12 months | 
| cancer incidence | Assess cancer incidence, on a population of people with kidney transplantation (since 10 years) : observation of adverse events during visits | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer
The Lamina Cribrosa (LC) Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)

Study Overview
=================
Brief Summary
-----------------
The burden of LASIK surgery on optic nerve head (ONH) has been controversial. Until now, the change of retinal nerve fiber layer (RNFL) thickness was used as the indicator of the study. In the present study, the investigators intended to investigate whether the changes of the deep and superficial structures around ONH exist or not using EDI OCT.

Official Title
-----------------
The Lamina Cribrosa (LC) Morphologic Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)

Conditions
-----------------
The Lamina Cribrosa and Optic Nerve Head Changes

Intervention / Treatment
-----------------
* Device: Exposed to the high pressure during the surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the myopic patients who were supposed to undergo LASIK surgery in the Samsung Medical Center Exclusion Criteria: Optic nerve head abnormalities at preoperative examination Previous ocular surgical history
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| LASIK<br> | Device: Exposed to the high pressure during the surgery<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of lamina cribrosa (LC) depth | micro millimeter | before the surgery, postoperative 1 day, 1 week, 1 month, and 3 months | 
| Change of lamina cribrosa (LC) thickness | micro millimeter | before the surgery, postoperative 1 day, 1 week, 1 month, and 3 months | 
| Change of optic nerve head (ONH) width | micro millimeter | before the surgery, postoperative 1 day, 1 week, 1 month, and 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of optic nerve head minimum rim width | micro millimeter | before the surgery, postoperative 1 day, 1 week, 1 month, and 3 months |
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®

Study Overview
=================
Brief Summary
-----------------
To describe severe late onset patients with pompe disease receiving Myozyme®

Official Title
-----------------
Observational Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme

Conditions
-----------------
Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenesis 2 Acid Maltase Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female ≥ 18 years of age; The patient and/or patient's legal representative has given their informed consent in writing before any study procedure is initiated; Pompe disease confirmed by documented deficit in endogenous acid alpha-glucosidase (GAA) activity; A severe form of the disease as defined as follows: a. Moderate to severe limb girdle muscle weakness requiring help for walking around (sticks, crutches, walking frame or wheelchair); and b. Symptoms of diaphragmatic dysfunction defined by at least 2 out of the 3 following criteria: orthopnea, vital capacity < 50%, paradoxical respiration detected in measurement of transdiaphragmatic pressure; and c. Use of invasive ventilation (defined by need for tracheotomy) or noninvasive ventilation (defined by utilization of assisted ventilation using a nasal or facial mask)day and night prescribed ≥ 12 hours/day; Treated for ≥6 months with Myozyme; Followed-up in a reference center according to the CETP recommendations. Exclusion Criteria: The patient presents with a major congenital anomaly; The patient presents with a clinically important organic disease (except for symptoms related to Pompe disease) such as cardiovascular, hepatic, pulmonary, neurological or renal disease or any other medical condition, serious disease or particular circumstances that in the investigator's opinion, should preclude the patient's participation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe severe late onset patients with Pompe disease receiving Myozyme and follow-up according to the CETP recommendations |  | 12 to 18 months |